在国庆中秋长假后的首个交易日，易方达港股通科技基金迎来首发，该产品募集上限为20亿元。刚刚，该基金宣布提前结募并启动末日比例配售。这也意 味着，募集仅2个发行日，产品吸金超过20亿元。 【导读】易方达港股通科技基金宣布提前结募并比例配售，吸金超20亿元 A股市场走好，新基金发行市场也捷报频传。 业内人士指出，随着权益市场逐渐回暖，主动权益类产品重新受到投资者的关注，因此该基金取得了不俗的发行成绩。同时，主动限制首发规模，更利于 保护投资者利益。 实际上，近期新基金频频提前结募，仅9月就有48只基金宣布提前结募，其中不少为权益类产品。多位业内人士认为，随着行情深入，权益类基金发行有 望持续回暖，并不断给市场带来增量资金。 又见提前结束募集 10月9日，易方达港股通科技混合基金迎来首发。10月10日，该基金就宣布提前结束募集。 "近期主动权益产品募集成绩较好，一方面是因为权益市场回暖，此类产品受到投资者重视，尤其是'实力派'基金经理管理产品；另一方面，基金托管行 的销售能力也是重要一环，拥有较好的客户基础的渠道能获得不错的发行成绩。"一位业内人士表示。 权益基金发行回暖 有望为市场带来更多增量资金 实际上，随着A ...

本文共2000 字 阅读完约5分钟 从发行市场的情况来看，进入9月以来，一日售罄的权益类基金在增多，主动权益类基金的发行数据也颇为靓丽。 数据显示，截至9月22日，9月以来成立的权益类基金中，共有7只一日售罄，其中6只是主动权益类基金。 招商均衡优选发行规模较大，该基金自9月2日开始发行，原定募集截止日为9月12日，同时设置了50亿元的募集规模上限，最终提前结束募集，仅售一 日。该基金于9月4日正式成立，募集规模为49.55亿元，最终认购申请确认比例仅为56.67%，这意味着当日认购资金或高达88亿元。该基金也成为今年以 来新发规模最大的主动权益型基金。近期该基金净值有所波动，显示已逐步建仓。 华商港股通价值回报基金也一日售罄。该基金自9月8日开始发行，原定募集截止日为9月24日，同时设置了10亿元的募集规模上限，最终仅售一日便超出 募集规模上限而提前结束募集，并按32.95%的末日比例确认认购份额，最终募集规模为9.9亿元。 金融投资报记者 刘庆华 伴随着A股市场的稳步上行，权益类基金发行市场逐渐回暖，9月以来权益类基金发行亮点频现。 一方面，多只权益类基金一日售罄，环比上月数量明显增多，包括招商均衡优选、 ...

Group 1 - In July, the public fund issuance saw a resurgence with nearly 150 new funds launched, marking a monthly issuance record for the year [1] - The strong market performance has led to increased investor sentiment, making it easier for fund companies to issue new products [1] - The optimism from fund companies regarding future market performance is reflected in the high issuance enthusiasm [1] Group 2 - As of August 3, over 90 of the 149 newly launched public funds in July have been established, with total fund issuance exceeding 800 billion units [2] - Bond funds dominated the issuance scale, accounting for more than half of the total, with the largest single product being Huatai-PineBridge's 6-month holding fund, which issued 3.741 billion units [2] - The first batch of Sci-Tech Bond ETFs was a highlight, with 10 ETFs collectively issuing over 28 billion units, representing nearly 40% of the total issuance for July [2] Group 3 - Equity fund issuance showed significant recovery, with 81 new stock funds launched in July, nearly 2.8 times that of the same period last year [3] - The issuance scale of stock funds in July was 5.7 times higher than last year, with stock funds accounting for 32.33% of total fund issuance [3] - The total issuance of stock funds in the first seven months of the year exceeded 210 billion, reflecting substantial growth compared to the previous year [3] Group 4 - Looking ahead, the issuance of equity funds is expected to continue to rise, supported by favorable market conditions and policies [4] - Over 60 public funds are scheduled to launch in August, with more than 80% being equity funds [4] - On August 4, 18 equity funds were launched, primarily consisting of actively managed funds [4] Group 5 - A second batch of 12 new floating fee rate products has been approved, including 2 stock funds and 10 mixed equity funds [5] - The new floating fee rate products are expected to align the interests of fund managers and investors, promoting healthy industry development [5] - The regulatory framework encourages leading fund management firms to issue floating fee rate funds, aiming for at least 60% of their active equity fund issuance [5]

Group 1 - The issuance of equity funds has shown a significant increase, with 7 equity funds established at the beginning of July, indicating a recovery in investor confidence and optimism towards the equity market [1][2] - Among the 67 funds currently being issued, 50 are equity funds, accounting for 74.63%, and 34 are passive index funds, making up 50.75% [2] - The trend of increasing equity fund issuance is expected to inject more capital into the market, enhancing liquidity and trading activity, while also fostering healthy competition among public fund institutions [2] Group 2 - Passive index funds are favored due to their clear investment style, high transparency, and standardization, which facilitates asset allocation [3] - The growing recognition of passive index funds among investors, along with their risk mitigation capabilities in volatile markets, has contributed to their appeal [3] - Public fund institutions are diversifying their product offerings, focusing on various indices and industry themes such as healthcare, robotics, and aerospace, reflecting their assessment of future investment opportunities [3][4] Group 3 - The healthcare sector is highlighted as a significant investment opportunity, with expectations of a major recovery in the innovative drug industry by 2025, driven by favorable policies and market conditions [4] - The Chinese innovative drug sector is anticipated to gain global market attention once clinical data is validated internationally, marking a substantial trend in the industry [4]

ETF Industry News - The three major indices collectively rose, with the Shanghai Composite Index up 0.43%, the Shenzhen Component Index up 0.65%, and the ChiNext Index up 1.07. Multiple innovative drug ETFs saw significant gains, including Tianhong Innovative Drug ETF (517380.SH) up 4.36%, Fortune Innovative Drug ETF (159748.SZ) up 3.57%, and Guotai Innovative Drug ETF (517110.SH) up 3.13% [1] - The bond ETF market has reached a significant milestone, surpassing 300 billion yuan in total scale, following the earlier milestone of 200 billion yuan in February. Notably, several bond ETFs have exceeded 48 billion yuan in scale, indicating structural growth in the bond ETF market [2] - A new wave of fund fee reductions has been implemented, with nearly 10 funds from various companies announcing fee cuts, primarily in bond products. This trend is expected to lower investment costs for investors [3] - The issuance of equity funds has seen a resurgence, with four new equity funds raising over 1 billion yuan since June, indicating a shift of funds towards high-performing funds and favored fund managers [4] Market Performance Overview - The overall performance of ETFs shows that cross-border ETFs had the best average performance with a rise of 1.47%, while commodity ETFs had the worst performance with an average decline of 0.86% [8] - The top-performing ETFs today included Tianhong Innovative Drug ETF (517380.SH) with a gain of 4.36%, Fortune Innovative Drug ETF (159748.SZ) with a gain of 3.57%, and Guotai Innovative Drug ETF (159377.SZ) with a gain of 3.50% [10][11] - The trading volume of ETFs today was led by A500 ETF (512050.SH) with a transaction amount of 2.855 billion yuan, followed by A500 Index ETF (159351.SZ) with 2.747 billion yuan, and CSI 300 ETF (510300.SH) with 2.323 billion yuan [13]